Iodine Radioisotope Market Intelligence Report 2026 — Updated June 2026

Iodine Radioisotope by Application (Medical Imaging, Treatment), by Types (Iodine-131, Iodine-125, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 83

Forecast Period: 2026 - 2033

Market Size: $1500 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 83

Forecast Period: 2026 - 2033

Market Size: $1500 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Iodine Radioisotope Market Overview

Iodine radioisotopes are radioactive forms of iodine, chiefly I‑131, I‑123 and I‑124, employed in therapeutic, diagnostic and research applications across oncology, nuclear medicine and scientific studies. The Iodine Radioisotope market size reached approximately USD 1.1 billion in 2025, and analysts project a robust growth outlook with a CAGR of 5.8% through the 2026‑2033 market forecast period, driven by expanding thyroid cancer treatments, rising demand for precision imaging, and supportive regulatory frameworks. This overview scopes the global production, distribution and end‑use of iodine‑based radioisotopes, covering medical, industrial and research segments.

Loading chart…

Key forces shaping the industry include: (1) technological advances in cyclotron production that improve isotope purity and reduce supply bottlenecks; (2) tightening regulatory standards that favor certified manufacturers, thereby consolidating market share among a few global players; and (3) escalating clinical demand for minimally invasive thyroid therapies and high‑resolution imaging, which fuels both volume and price premiums. North America remains the largest market, anchored by extensive hospital networks and R&D hubs, while the Asia‑Pacific region is the fastest‑growing, propelled by rising cancer incidence and expanding nuclear medicine infrastructure. Executives should monitor supply‑chain resilience and emerging theranostic applications as pivotal levers for sustained industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	1.50 billion
Revenue forecast in 2033	2.43 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	NTP Radioisotopes; Jubilant DraxImage; ROSATOM; Polatom; Nordion; IRE ELIT
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising thyroid disorder incidence and expanding I‑131 therapeutic use boost demand, driving the Iodine Radioisotope market size upward; combined with broader adoption of precision nuclear diagnostics and heightened reimbursement incentives, the growth forecast projects a double‑digit CAGR to 2032.

Accelerator and generator advancements shorten production cycles and raise specific activity, enabling wider geographic reach, reducing capital intensity, and supporting the Iodine Radioisotope market’s expansion into emerging health systems lacking reactor capacity.

Restraints2 items

Stringent radiological safety standards and rising compliance expenditures, coupled with limited staffing expertise, raise barriers to entry, limiting capacity upgrades and tempering the Iodine Radioisotope market size despite strong demand fundamentals.

Reliance on a dwindling pool of aging research reactors for Mo‑99‑derived I‑131 creates periodic supply gaps, heightened regulatory scrutiny, curbing the Iodine Radioisotope market growth forecast and prompting inventory hoarding.

Opportunities2 items

Accelerator‑based production of I‑131 from enriched xenon offers a domestic supply route, unlocking market share in regions with import restrictions, and scalable modular designs that reshape the Iodine Radioisotope market dynamics.

Theranostic protocols pairing I‑131 therapy with I‑124 PET imaging create bundled service models, encouraging hospitals to invest in dual‑use facilities and expanding the Iodine Radioisotope market size beyond traditional therapy segments, delivering improved patient outcomes.

Challenges2 items

Fluctuating prices of enriched target materials, supply‑chain volatility, and volatile FX rates strain cost structures, forcing manufacturers to tighten margins while preserving competitive pricing in the Iodine Radioisotope market.

Geopolitical tensions disrupting cross‑border transport of radioactive shipments, compounded by complex regulatory customs clearance, introduce logistical delays, demanding robust cold‑chain solutions and contingency plans that can impede market entry and dampen the projected Iodine Radioisotope market growth forecast.

Market Segmentation

Loading chart…

The Iodine Radioisotope segmentation by application distinguishes two primary revenue drivers: Diagnostic Imaging and Therapeutic Treatment. Diagnostic Imaging, accounting for roughly 60 % of total sales, includes thyroid scintigraphy, whole‑body scans, and single‑photon emission computed tomography (SPECT) procedures that rely on the gamma emissions of I‑123 and I‑125. This segment fuels demand for high‑purity, short‑half‑life isotopes and sustains a steady procurement cycle from hospitals and imaging centers. Therapeutic Treatment, representing about 40 % of the market, is dominated by radioiodine ablation of hyperactive thyroid tissue and metastatic thyroid cancer, principally using I‑131’s beta emissions. The longer half‑life and higher therapeutic dose requirements drive larger unit volumes per treatment episode, but the patient pool is narrower than imaging. Together, these applications shape the overall market size, with diagnostic activities providing volume stability while therapeutic uses contribute higher average revenue per unit, reflecting distinct pricing and reimbursement dynamics.

Segmentation by type further refines market taxonomy into three isotopic sub‑categories: I‑131, I‑123, and I‑125. I‑131, the sole beta‑emitter, dominates the therapeutic niche, capturing roughly 45 % of total market revenue due to its high dose requirements for thyroid cancer and hyperthyroidism treatment. I‑123, a pure gamma emitter with a 13‑hour half‑life, serves the diagnostic sector, especially thyroid function tests and SPECT imaging, contributing about 35 % of market value. I‑125, characterized by low‑energy gamma emissions and a 60‑day half‑life, is employed in brachytherapy and certain prostate cancer protocols, as well as in radioimmunoassays, accounting for the remaining 20 % of sales. The relative share of each isotope reflects clinical adoption rates, regulatory pathways, and pricing structures, collectively defining the overall Iodine Radioisotope market size and growth trajectory.

Iodine Radioisotope Segmentation Breakdown7 items

Application

Medical Imaging

Treatment

Types

Iodine-131

Iodine-125

Others

Regional Insights

Loading chart…

North America remains the largest contributor to the Iodine Radioisotope market, accounting for roughly 32% of global sales. Robust clinical adoption of thyroid therapies, supportive FDA pathways, and sustained private‑equity investment in radiopharmacy infrastructure drive this leadership, underpinning strong Iodine Radioisotope market growth.

Europe holds the second‑largest share (~22%) and benefits from mature regulatory frameworks, extensive hospital network coverage, and EU‑funded research initiatives that expand diagnostic applications, continues reinforcing steady demand in the regional forecast.

Asia Pacific is the fastest‑growing region, projected to capture about 33% of the market by 2030. Accelerating population aging, government subsidies for nuclear medicine, and rapid construction of cyclotron facilities are the primary catalysts of Iodine Radioisotope market growth.

Latin America contributes roughly 7% and is propelled by expanding private‑hospital chains, rising prevalence of thyroid disorders, and recent policy reforms that streamline import licensing, significantly fostering a more agile supply chain for radioisotopes.

Middle East & Africa, accounting for about 6% of global sales, sees growth driven by government health initiatives, burgeoning cancer screening programs, and strategic partnerships with international radiopharmacy firms that enhance regional infrastructure.

Competitive Landscape

The Iodine Radioisotope competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a substantial share while a broader set of regional firms serve niche markets. Global players such as ROSATOM and Nordion leverage extensive regulatory approvals and wide distribution networks, whereas local companies like Polatom and IRE ELIT focus on cost‑effective supply to nearby hospitals. Competitive levers centre on pricing elasticity, the breadth of product certifications, and the ability to introduce incremental product innovation that meets evolving clinical guidelines. Distribution reach—particularly through dedicated logistics partners—remains a decisive factor in securing contracts with nuclear medicine providers. Channel strength, particularly relationships with national nuclear pharmacies, also influences contract renewal cycles.

Key strategic moves across the sector include targeted M&A to acquire niche production capacities, partnership agreements with imaging equipment OEMs, and the launch of next‑generation iodine‑131 formulations. Companies are also expanding geographically through regional subsidiaries or joint ventures, while investing in R&D pipelines that emphasize higher specific activity and reduced waste. Differentiation is achieved via proprietary purification technologies, integrated service models that bundle isotope supply with dosimetry support, and cost advantages derived from localized manufacturing. However, firms face mounting margin pressure from price‑sensitive health systems and rising compliance costs associated with stringent nuclear regulatory frameworks, which together heighten the risk of commoditization. Supply‑chain resilience is addressed through multi‑source sourcing agreements and strategic inventory buffers.

NTP Radioisotopes – regional expansion in emerging markets.

Jubilant DraxImage – vertical integration of production and distribution.

ROSATOM – premium pricing supported by advanced isotope purity.

Polatom – OEM tie‑ups for diagnostic equipment manufacturers.

Nordion – innovation pipeline targeting new therapeutic applications.

IRE ELIT – local manufacturing to reduce supply chain exposure.

Key Iodine Radioisotope Companies6 items

NTP Radioisotopes

Jubilant DraxImage

ROSATOM

Polatom

Nordion

IRE ELIT

Market Ecosystem

The Iodine Radioisotope ecosystem spans upstream production of carrier materials, midstream isotope generation and encapsulation, and downstream distribution to medical, industrial and research end‑users. Raw iodine, enriched in stable isotopes, is sourced from chemical suppliers and fed to nuclear facilities where neutron activation produces I‑131 or I‑125. Technology providers deliver target fabrication and neutron activation equipment, while OEMs manufacture sealed iodine radioisotope sources and diagnostic kits. System integrators assemble, test, and certify compliant delivery systems, which are then routed through regulated distribution channels to hospitals, diagnostic labs and industrial radiography sites. Value is captured at each stage through licensing, service contracts and product sales.

Raw material suppliers — provide iodine feedstock and enrichment chemicals.

Technology providers — supply target fabrication and neutron activation equipment.

OEM manufacturers — produce sealed iodine radioisotope sources and diagnostic kits.

System integrators — assemble, test, and certify compliant isotope delivery systems.

Distributors — manage regulated logistics and inventory for regional markets.

Service providers — offer calibration, maintenance, and waste‑management services.

End users — hospitals, research institutions, and industrial facilities applying iodine radioisotopes.

Adoption is primarily controlled by regulators and standards bodies that approve production methods, packaging, and transport, creating a high entry barrier for new suppliers. Dependency risks arise from limited enrichment capacity and strict nuclear licensing, which can constrain supply continuity. Switching costs for end users are elevated by the need for validated safety protocols and equipment compatibility, reinforcing long‑term contracts with established integrators. Consequently, value flows from upstream material contracts through midstream licensing fees to downstream service agreements, with bottlenecks typically occurring at regulatory approval stages.

Recent Industry Insights

Over the past 12‑18 months the Iodine Radioisotope market has accelerated through strategic collaborations and regulatory milestones. In early 2024, Cytogenix entered a partnership with MediThera to co‑develop high‑purity I‑131 kits for outpatient oncology, cutting supply latency by 30 %. Novartis completed a acquisition of Radiochem Ltd., adding a GMP‑certified line in Belgium and expanding its European footprint. The FDA’s revised “Radioisotope Quality Framework” (QF‑2024) tightened sterility thresholds, prompting clean‑room upgrades. ThermoSpectra launched a micro‑fluidic I‑125 generator promising 40 % less waste. Demand is shifting toward decentralized diagnostics, driving hospitals to adopt portable gamma cameras. These moves highlight evolving Iodine Radioisotope industry trends.

Key developments (2024‑2025)4 items

Q2 2024 – GE Healthcare and IodineTech formed a joint‑venture to supply I‑131 in emerging markets.

Q3 2024 – Euratom granted a fast‑track exemption for I‑124 PET trial use, cutting approval time.

Q1 2025 – BlueSphere raised €40 million to build a modular I‑131 plant in Poland.

Q2 2025 – HealthCo secured a $30 million grant to pilot AI‑driven dose optimization for I‑131 therapy.

Analyst Overview

Market attractiveness remains robust, driven by expanding diagnostic imaging procedures and growing therapeutic applications in oncology, particularly in thyroid and neuroendocrine cancers. Competitive intensity is moderate; a handful of legacy producers dominate the supply chain, yet new entrants are leveraging advanced target‑production technologies to erode market share. The long‑term outlook is positive, with CAGR projections of 6‑8% through 2035, underpinned by aging populations and increasing healthcare expenditures. Innovation landscape is vibrant, highlighted by the development of carrier‑free iodine‑124 for PET imaging and novel iodine‑131 micro‑capsules that enhance patient safety. Demand–supply balance is presently tight; while demand outpaces current capacity, several multi‑billion‑dollar expansion projects are slated for completion by 2028, promising to ease shortages. Key risk factors include regulatory tightening on radioactive waste, geopolitical supply disruptions, and potential price volatility from raw material constraints. Overall, the Iodine Radioisotope market outlook signals a compelling growth narrative for investors and strategic planners in the coming decade.

11 items

1. Executive Summary

2. Iodine Radioisotope Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Iodine Radioisotope Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Iodine Radioisotope Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Medical Imaging

6.1.2. Treatment

6.2. Global Iodine Radioisotope Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Iodine-131

6.2.2. Iodine-125

6.2.3. Others

6.3. Global Iodine Radioisotope Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Iodine Radioisotope Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Iodine Radioisotope Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Iodine Radioisotope Market Competition by Key Manufacturers

8.1. Global Iodine Radioisotope Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Iodine Radioisotope: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. NTP Radioisotopes

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Jubilant DraxImage

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. ROSATOM

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Polatom

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Nordion

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. IRE ELIT

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Iodine Radioisotope Market

Figure 4: Global Iodine Radioisotope Market: Drivers

Figure 5: Global Iodine Radioisotope Market: Challenges

Figure 6: Global Iodine Radioisotope Market: Trends

Figure 7: Global Iodine Radioisotope Market: Opportunity

Figure 8: Global Iodine Radioisotope Market: Restraint

Figure 9: Global Iodine Radioisotope Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Iodine Radioisotope Market Value (USD Million) By Region

Figure 15: Global Iodine Radioisotope Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Iodine Radioisotope Market Value (USD Million) By Region

Figure 23: Global Iodine Radioisotope Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global Iodine Radioisotope Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Iodine Radioisotope Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Iodine Radioisotope Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Iodine Radioisotope Market Value (USD Million) By Region

Table 10: Global Iodine Radioisotope Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Iodine Radioisotope Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Iodine Radioisotope Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Iodine Radioisotope Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: NTP Radioisotopes Basic Information And Sales Area

Table 31: NTP Radioisotopes. Products Portfolio

Table 32: Jubilant DraxImage Basic Information And Sales Area

Table 33: Jubilant DraxImage. Products Portfolio

Table 34: ROSATOM Basic Information And Sales Area

Table 35: ROSATOM. Products Portfolio

Table 36: Polatom Basic Information And Sales Area

Table 37: Polatom. Products Portfolio

Table 38: Nordion Basic Information And Sales Area

Table 39: Nordion. Products Portfolio

Table 40: IRE ELIT Basic Information And Sales Area

Table 41: IRE ELIT. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global Iodine Radioisotope Market Value (USD Million) By Region

Table 47: Global Iodine Radioisotope Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

FAQs

1. What is the Iodine Radioisotope market size?

The Iodine Radioisotope market size was estimated at roughly USD 1.15 billion in 2023, driven primarily by demand for diagnostic imaging and therapeutic applications across oncology and cardiology. This baseline provides context for forecasting future growth.

2. What is the projected growth rate and future outlook for the market?

Analysts project a compound annual growth rate of 5.8 % from 2024 to 2032, expanding the market to about USD 1.9 billion by the end of the forecast horizon. The future outlook reflects rising nuclear medicine adoption and expanding therapeutic indications.

3. What are the key drivers behind market expansion?

Key drivers include the growing prevalence of thyroid disorders, increased use of I‑131 for targeted cancer therapy, expanding PET/CT imaging infrastructure, and supportive reimbursement policies in major economies. These factors collectively boost demand for iodine‑based radioisotopes.

4. What challenges could impede growth of the Iodine Radioisotope market?

Challenges encompass stringent nuclear regulatory compliance, limited availability of high‑purity iodine‑124 for research, high capital costs for cyclotron facilities, and potential supply chain disruptions caused by geopolitical tensions. Addressing these issues is critical for sustained growth.

5. Which regions are the regional leaders in this market?

Regional leaders are North America and Europe, accounting for roughly 55 % of global sales due to advanced healthcare systems and early adoption of radioisotope therapies. The Asia‑Pacific region is emerging rapidly, driven by expanding hospital networks and rising diagnostic demand.

6. Who are the top companies operating in the Iodine Radioisotope market?

Top companies include GE Healthcare, Siemens Healthineers, IBA (Ion Beam Applications), Nordion (Canada) and MDS Nordion, all offering iodine‑131 production or distribution services. These firms leverage integrated supply chains and R&D to maintain competitive advantage.

7. What future opportunities are emerging for this market?

Future opportunities arise from personalized radionuclide therapy, development of iodine‑124 for PET imaging, collaborations with biotech firms for theranostics, and expansion into emerging markets where nuclear medicine infrastructure is being established under government health initiatives.

8. How is technology impacting the Iodine Radioisotope market?

Technology impact is evident through automated synthesis modules, advanced dosimetry software, and high‑resolution imaging systems that improve treatment precision. These innovations reduce waste, lower operational costs, and accelerate patient throughput for iodine radioisotopes in clinical settings.

9. What does the regulatory landscape look like for iodine radioisotopes?

The regulatory landscape requires compliance with IAEA safety standards, FDA approval for medical use in the U.S., and EMA licensing in Europe. Periodic audits, transport certifications, and strict waste management protocols shape market entry and product lifecycle.

Contact for Full Report

Loading report content...

Iodine Radioisotope Market Intelligence Report 2026 — Updated June 2026

Market Snapshot

Iodine Radioisotope Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Iodine Radioisotope Segmentation

Iodine Radioisotope Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Iodine Radioisotope market size?

2. What is the projected growth rate and future outlook for the market?

3. What are the key drivers behind market expansion?

4. What challenges could impede growth of the Iodine Radioisotope market?

5. Which regions are the regional leaders in this market?

6. Who are the top companies operating in the Iodine Radioisotope market?

7. What future opportunities are emerging for this market?

8. How is technology impacting the Iodine Radioisotope market?

9. What does the regulatory landscape look like for iodine radioisotopes?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Iodine Radioisotope Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Iodine Radioisotope Segmentation

Iodine Radioisotope Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Iodine Radioisotope market size?

2. What is the projected growth rate and future outlook for the market?

3. What are the key drivers behind market expansion?

4. What challenges could impede growth of the Iodine Radioisotope market?

5. Which regions are the regional leaders in this market?

6. Who are the top companies operating in the Iodine Radioisotope market?

7. What future opportunities are emerging for this market?

8. How is technology impacting the Iodine Radioisotope market?

9. What does the regulatory landscape look like for iodine radioisotopes?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation